Buch, Englisch, Band 18, 158 Seiten, Previously published in hardcover, Format (B × H): 155 mm x 235 mm, Gewicht: 271 g
Buch, Englisch, Band 18, 158 Seiten, Previously published in hardcover, Format (B × H): 155 mm x 235 mm, Gewicht: 271 g
Reihe: Resistance to Targeted Anti-Cancer Therapeutics
ISBN: 978-3-030-08652-7
Verlag: Springer International Publishing
This volume, in discussing resistance to ibritumomab, will focus on the mechanism, hematological aspects, radiological and nuclear medicine aspects, and medical physics that deal with radiation dosimetry, and will outline future prospects for overcoming resistance and enhancing efficacy of ibritumomab.
Zielgruppe
Research
Autoren/Hrsg.
Fachgebiete
Weitere Infos & Material
Clinical Use and Efficacy of Ibritumomab in B-cell Lymphoma.- Biology and Pathology of B-cell lymphoma.- Resistance to Y-90 Ibritumomab Tiuxetan Therapy.- Features of Ibritumomab as Radionuclide Therapy.- Radiological Evaluation of Response and Resistance of Ibritumomab.- Characteristics of Ibritumomab as Radionuclide Therapy Agent.- Resistance and Heterogeneity of Intratumoral Antibody Distribution.- Radiation Dosimetry in Ibritumomab Therapy.- Combining RAIT and immune-based therapies to overcome resistance in cancer?.- Prospects for enhancing efficacy of radioimmunotherapy.- Index.